Gyre Therapeutics (GYRE) Net Income Attributable to Noncontrolling Interests (2011 - 2026)
Gyre Therapeutics (GYRE) recorded Income from Non-Controlling Interests of -$3.67 million in Q2 2026, compared with -$2.84 million a year earlier.
Powered by 
Analysis
Gyre Therapeutics (GYRE) Net Income Attributable to Noncontrolling Interests (2011 - 2026) Analysis & Trends
On a TTM basis, Gyre Therapeutics' Income from Non-Controlling Interests came in at -$2.15 million as of Jun 30, 2026; for FY2025, it was $4.85 million, down 16.5% from FY2024.
- Annual Income from Non-Controlling Interests has a three-year compound annual growth rate of 34.1% (FY2022 to FY2025).
- Across earlier years, Income from Non-Controlling Interests came in at $5.81 million in FY2024 (-22.0%), $7.45 million in FY2023 (+270.4%) and $2.01 million in FY2022.
- The Q2 2026 figure is the lowest quarterly Income from Non-Controlling Interests in data going back to Q1 2023.
- On a year-over-year basis, Income from Non-Controlling Interests rose in 1 of the last four quarters, with an average decline of 30.0%.
- Per Business Quant, the preceding three quarters came in at -$1.17 million (Q1 2026), $357,000 (Q4 2025) and $2.33 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCI Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | - |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | - |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 2.00 Mn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 2.00 Mn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | - |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | -1.00 Mn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | - |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | - |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 10.00 Mn |
| 10 | Gyre Therapeutics | 487.81 Mn | 295.13 Mn | 30.99 Mn | 1.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 1.58 Mn |
| Jun 30, 2026 | -3.67 Mn |
| Mar 31, 2026 | -1.17 Mn |
| Dec 31, 2025 | 9.30 Mn |
| Sep 30, 2025 | -1.81 Mn |
| Jun 30, 2025 | -2.84 Mn |
| Mar 31, 2025 | 1.04 Mn |
| Dec 31, 2024 | 668,000.00 |
| Sep 30, 2024 | 1.73 Mn |
| Jun 30, 2024 | 1.01 Mn |
| Mar 31, 2024 | 2.40 Mn |
| Dec 31, 2023 | 29,000.00 |
| Sep 30, 2023 | 3.53 Mn |
| Jun 30, 2023 | 1.92 Mn |
| Mar 31, 2023 | 1.97 Mn |
| Jun 30, 2012 | 14.46 Mn |
| Jun 30, 2011 | -2.26 Mn |
API Access
Gyre Therapeutics Net Income Attributable to Noncontrolling Interests API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=GYRE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "income-from-non-controlling-interests", "ticker": "GYRE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=income-from-non-controlling-interests&ticker=GYRE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();